NCT07863648Not yet recruitingPhase 3
Vitamin E Versus Silymarin in Non Diabetic MASLD Patients
A Randomized Controlled Evaluation of Vitamin E Versus Silymarin on Liver Through Modulation of mRNA Profiles, NLRP3 Inflammasome Signaling, and Oxidative Stress in Non Diabetic MASLD Patients
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), is a chronic liver condition marked by excessive fat buildup (steatosis) in liver cells, linked to at least one metabolic risk factor like obesity, type 2 diabetes, high blood lipids, or hypertension. Vitamin E serves as a recommended antioxidant therapy for select MASLD patients. It reduces liver inflammation markers such as ALT and AST, alongside benefits in steatosis and MASH resolution. Silymarin has clinical evidence supports its use as an adjunctive hepatoprotective agent due to antioxidant, anti-inflammatory, and antifibrotic effects.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 2 Oct 2026
- Start date
- 16 Oct 2026
- Primary completion date
- 1 Aug 2027
- Lead sponsor
- Kafrelsheikh University
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07863648
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 120
- From 16 Oct 2026 to the primary completion date, 1 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Decompensated liver disease,
- Other liver diseases, decompensated cirrhosis,
Other
- Cirrhosis (LSM \>12 kPa),
- Pregnancy, or
- use of vitamin E/silymarin within 3 months.
Who the study is looking for
- Adults (18-65 y),
- Diagnosed with MASLD (CAP ≥248 dB/m on FibroScan, ALT \>40 IU/L),
- Non-diabetic (HbA1c \<6.5%, fasting glucose \<126 mg/dL),
- BMI 25-40 kg/m²,
- No alcohol (\>20 g/d women, \>30 g/d men).
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.